[The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
The currently approved coxibs celecoxib and etoricoxib, have an equivalent effect in comparison with conventional NSAIDs. This has been established both in comparative studies and by several years of practical application. While celecoxib is approved only for the symptomatic treatment of arthrosis and rheumatoid arthritis, etoricoxib can also be employed in the treatment of acute attacks of gout.